Literature DB >> 9254062

Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins.

E H Ludwig1, P N Hopkins, A Allen, L L Wu, R R Williams, J L Anderson, R H Ward, J M Lalouel, T L Innerarity.   

Abstract

To search for unique mutations in the apolipoprotein B (apoB) gene that disrupt the binding of LDL to its receptor and cause hypercholesterolemia, we examined more than 800 patients with high LDL cholesterol levels and/or coronary artery disease (CAD). Analysis of patient DNA by single-strand conformation polymorphism and allele-specific oligonucleotide hybridization of the sequence surrounding the putative receptor- binding domain of apoB (amino acid positions 2965 to 3534) revealed seven variations. LDL from heterozygotes with either Arg 3500 Gln or Arg 3531 Cys bound defectively with the LDL receptor in competitive binding assays. The Arg 3500 Gln substitution was statistically more prevalent in patients with hypercholesterolemia (P = 0.0003). Total cholesterol and LDL-cholesterol were significantly higher (P< 0.0004) in 34 apoB 3500 Gln carriers than in the controls. The allele encoding the Arg 3531 Cys substitution was more prevalent (0.8%) in the CAD group (P = 0.05) than in the controls. A Ser 3252 Gly variant was statistically more prevalent in the hypercholesterolemic group (P = 0.03), but LDL with this mutation had normal LDL receptor-binding activity. The other four variants identified (Leu 3350 Leu, Gln 3405 Glu, Val 3396 Met, and Ser 3455 Arg) were not associated with defective LDL-receptor binding, hypercholesterolemia, or CAD, nor were the apoB mutations associated with elevated lipid levels in family members. The surprising result that only two mutations of apoB in the receptor-binding domain (Arg 3500 Gln and Arg 3531 Cys) were associated with defective LDL binding, hypercholesterolemia, or CAD is in stark contrast with familial hypercholesterolemia, where nearly 150 mutations of the LDL receptor have been described that disrupt its function. This study strongly suggests that a limited number of mutations of apoB markedly influence LDL binding to its receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9254062

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

Authors:  J Borén; K Olin; I Lee; A Chait; T N Wight; T L Innerarity
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

2.  Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish.

Authors:  Haiqing Shen; Coleen M Damcott; Evadnie Rampersaud; Toni I Pollin; Richard B Horenstein; Patrick F McArdle; Patricia A Peyser; Lawrence F Bielak; Wendy S Post; Yen-Pei C Chang; Kathleen A Ryan; Michael Miller; John A Rumberger; Patrick F Sheedy; John Shelton; Jeffrey R O'Connell; Alan R Shuldiner; Braxton D Mitchell
Journal:  Arch Intern Med       Date:  2010-11-08

3.  Familial Hypercholesterolemia.

Authors:  Paul N. Hopkins
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-04

4.  Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations.

Authors:  J Wang; D J Freeman; S M Grundy; D M Levine; R Guerra; J C Cohen
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

6.  Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study.

Authors:  Manal S Fawzy; Eman A Toraih; Nagwa M Aly; Abeer Fakhr-Eldeen; Dahlia I Badran; Mohammad H Hussein
Journal:  BMC Cardiovasc Disord       Date:  2017-01-13       Impact factor: 2.298

7.  Identification of a pleiotropic effect of ADIPOQ on cardiac dysfunction and Alzheimer's disease based on genetic evidence and health care records.

Authors:  Hyojung Paik; Junehawk Lee; Chan-Seok Jeong; Jun Sung Park; Jeong Ho Lee; Nadav Rappoport; Younghoon Kim; Hee-Young Sohn; Chulman Jo; Jimin Kim; Seong Beom Cho
Journal:  Transl Psychiatry       Date:  2022-09-16       Impact factor: 7.989

8.  Abdominal obesity, blood glucose and apolipoprotein B levels are the best predictors of the incidence of hypercholesterolemia (2001-2006) among healthy adults: the ATTICA study.

Authors:  Demosthenes B Panagiotakos; Christos Pitsavos; Yannis Skoumas; Yannis Lentzas; Labros Papadimitriou; Christina Chrysohoou; Christodoulos Stefanadis
Journal:  Lipids Health Dis       Date:  2008-03-31       Impact factor: 3.876

9.  Genetic Polymorphisms in a Familial Hypercholesterolemia Population from North-Eastern Europe.

Authors:  Alexandra Maștaleru; Sabina Alexandra Cojocariu; Andra Oancea; Maria Magdalena Leon Constantin; Mihai Roca; Ioana Mădălina Zota; Irina Abdulan; Cristina Rusu; Roxana Popescu; Lucian Mihai Antoci; Cristian Gabriel Ciobanu; Alexandru Dan Costache; Elena Cojocaru; Florin Mitu
Journal:  J Pers Med       Date:  2022-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.